Authors:
George, DJ
Halabi, S
Shepard, TF
Vogelzang, NJ
Hayes, DF
Small, EJ
Kantoff, PW
Citation: Dj. George et al., Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer andleukemia group B 9480, CLIN CANC R, 7(7), 2001, pp. 1932-1936
Authors:
Savarese, DM
Halabi, S
Hars, V
Akerley, WL
Taplin, ME
Godley, PA
Hussain, A
Small, EJ
Vogelzang, NJ
Citation: Dm. Savarese et al., Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780, J CL ONCOL, 19(9), 2001, pp. 2509-2516
Authors:
Kantoff, PW
Halabi, S
Farmer, DA
Hayes, DF
Vogelzang, NA
Small, EJ
Citation: Pw. Kantoff et al., Prognostic significance of reverse transcriptase polymerase chain reactionfor prostate-specific antigen in men with hormone-refractory prostate cancer, J CL ONCOL, 19(12), 2001, pp. 3025-3028
Authors:
Bok, RA
Halabi, S
Fei, DT
Rodriquez, CR
Hayes, DF
Vogelzang, NJ
Kantoff, P
Shuman, MA
Small, EJ
Citation: Ra. Bok et al., Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study, CANCER RES, 61(6), 2001, pp. 2533-2536
Authors:
Sandler, RS
Halabi, S
Kaplan, EB
Baron, JA
Paskett, E
Petrelli, NJ
Citation: Rs. Sandler et al., Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial, CANCER, 91(5), 2001, pp. 1040-1045
Authors:
McBride, CM
Halabi, S
Bepler, G
Lyna, P
McIntyre, L
Lipkus, I
Albright, J
O'Briant, K
Citation: Cm. Mcbride et al., Maximizing the motivational impact of feedback of lung cancer susceptibility on smokers' desire to quit, J HEAL COMM, 5(3), 2000, pp. 229-241
Authors:
Abou Nader, M
Halabi, S
Rachid, B
Beayni, C
Ali, M
Citation: M. Abou Nader et al., Neglected craniocerebral gunshot wound resulting in an encephalocele: Casereport, SURG NEUROL, 54(5), 2000, pp. 397-400
Authors:
Schildkraut, JM
Halabi, S
Bastos, E
Marchbanks, PA
McDonald, JA
Berchuck, A
Citation: Jm. Schildkraut et al., Prognostic factors in early-onset epithelial ovarian cancer: A population-based study, OBSTET GYN, 95(1), 2000, pp. 119-127
Authors:
Dawson, NA
Conaway, M
Halabi, S
Winer, EP
Small, EJ
Lake, D
Vogelzang, NJ
Citation: Na. Dawson et al., A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma - Cancer and leukemia group B study 9181, CANCER, 88(4), 2000, pp. 825-834
Authors:
Johnson, ES
Halabi, S
Netto, G
Lucier, G
Bechtold, W
Henderson, R
Citation: Es. Johnson et al., Detection of low level benzene exposure in supermarket wrappers by urinarymuconic acid, BIOMARKERS, 4(2), 1999, pp. 106-117
Authors:
Burns, CP
Halabi, S
Clamon, GH
Hars, V
Wagner, BA
Hohl, RJ
Lester, E
Kirshner, JJ
Vinciguerra, V
Paskett, E
Citation: Cp. Burns et al., Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: Cancer and leukemia group B study 9473, CLIN CANC R, 5(12), 1999, pp. 3942-3947
Authors:
Bastian, LA
McBride, CM
Halabi, S
Fish, LJ
Skinner, CS
Kaplan, EB
Bosworth, HB
Rimer, BK
Siegler, IC
Citation: La. Bastian et al., Attitudes and knowledge associated with being undecided about hormone replacement therapy: Results from a community sample, WOM HEAL IS, 9(6), 1999, pp. 330-337
Authors:
Kantoff, PW
Halabi, S
Conaway, M
Picus, J
Kirshner, J
Hars, V
Trump, D
Winer, EP
Vogelzang, NJ
Citation: Pw. Kantoff et al., Hydrocortisone with or without mitoxantrone in men with hormone-refractoryprostate cancer: Results of the Cancer and Leukemia Group B 9182 study, J CL ONCOL, 17(8), 1999, pp. 2506-2513
Authors:
Bubley, GJ
Carducci, M
Dahut, W
Dawson, N
Daliani, D
Eisenberger, M
Figg, WD
Freidlin, B
Halabi, S
Hudes, G
Hussain, M
Kaplan, R
Myers, C
Oh, W
Petrylak, DP
Reed, E
Roth, B
Sartor, O
Scher, H
Simons, J
Sinibaldi, V
Small, EJ
Smith, MR
Trump, DL
Vollmer, R
Wilding, G
Citation: Gj. Bubley et al., Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group, J CL ONCOL, 17(11), 1999, pp. 3461-3467
Authors:
Savarese, D
Taplin, ME
Halabi, S
Hars, V
Kreis, W
Vogelzang, N
Citation: D. Savarese et al., A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780, SEMIN ONCOL, 26(5), 1999, pp. 39-44
Authors:
Anreder, MB
Freeman, SM
Merogi, A
Halabi, S
Marrogi, AJ
Citation: Mb. Anreder et al., p53, c-erbB2, and PCNA status in benign, proliferative, and malignant ovarian surface epithelial neoplasms - A study of 75 cases, ARCH PATH L, 123(4), 1999, pp. 310-316